Ayana Pharma Overview
Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma. Co-founded by one of Doxils co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Can zero gravity help cure cancer? Israelis sent a drug to space to find out
An Israeli cancer drug called Doxil has returned to Earth after being tested on the International Space Station (ISS) to determine if it is more effective in microgravity. The inventor of Doxil, Prof. Yehezkel Bernholtz, is analyzing the results to see if treating cancer patients in space-like conditions could have benefits. The drug was sent to the ISS in January and has now returned to Earth for further analysis. The potential of exomedicine, the study of medicine in zero gravity, is of interest to NASA and others. Doxil is considered well-suited for space studies due to its complex structure. The results of the analysis are expected to provide insights into the impact of microgravity on the drug and its effectiveness against cancer cells.
Partners
growth-positive
Huston, we're solving cancer problems...
Ayana Pharmas cancer treatment drug, Doxil, was launched to the International Space Station as part of SpaceXs mission. The drugs launch was made possible by Israeli start-up SpacePharmas smart laboratory. The purpose of the experiment is to test if Doxil would change in zero-gravity conditions and to understand its effectiveness in non-gravity conditions. Ayana Pharmas drug development was led by Prof. Yehezkel Bernholtz, and the companys main investors include the Education Fund for Teachers and Kindergarten Teachers in Israel, the Integra Holdings Fund, the Ilan Holdings Fund, and Dr. Shmuel Kabili.
Partners
Generic, cancer-killing Israeli drug approved for marketing by FDA
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 1 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.ayanapharma.com/ |
Locations
Ein Kerem Street 95744, Jerusalem, Israel
Photos & Videos
No files yet
